SomaLogic, Inc. has entered into a multi-year research agreement with Novartis to use its proteomics technology to accelerate Novartis’ drug discovery and development efforts. Terms of the agreement were not disclosed. “We are excited by this opportunity to work with Novartis’ world-class researchers to help them define robust biomarkers, validate novel drug targets, and even develop companion clinical diagnostics,” said Larry Gold, chief executive officer of SomaLogic. ...